SNMMI: Lu-177 PSMA-617 shines for taxane-naive prostate cancer
AuntMinnie
JUNE 11, 2024
He presented the abstract on behalf of first author Ken Herrmann, MD, chair of nuclear medicine at the University Hospital Essen in Essen, Germany. Radiographic progression-free survival (rPFS) was the primary endpoint of the study, while overall survival was the key secondary endpoint. The hazard ratio was 0.43
Let's personalize your content